Category: Pharma

Clinical Trials, Industry, Pharma, Research and Development

Pfizer drug bests Sanofi, Regeneron’s Dupixent in head-to-head study

August 30, 2021

Via: Biopharma Dive

Abrocitinib is one of Pfizer’s top experimental therapies, pegged by the drugmaker for several billion dollars in peak annual sales in the future. But its fate, along with the fate of two other drugs from AbbVie and Lilly that are […]

Industry, Pharma

Pharmacies Face Extra Audit Burdens That Threaten Their Existence

August 6, 2021

Via: Kaiser Health News

The clock was about to strike midnight, and Scott Newman was desperately feeding pages into a scanner, trying to prevent thousands of dollars in prescription payments from turning into a pumpkin. As the owner of Newman Family Pharmacy, an independent […]

Industry, Pharma

Pfizer’s immunology ambitions delayed—again—as JAK drugs fall victim to FDA’s protracted safety review

July 22, 2021

Via: FiercePharma

Pfizer and its JAK inhibitors are falling deeper down a regulatory rabbit hole the company itself opened up. The FDA has once again pushed back two decisions key to Pfizer’s immunology franchise: Xeljanz in ankylosing spondylitis and abrocitinib in atopic […]

Cell and Gene Therapy, Industry, News, Pharma

Iksuda Therapeutics raises $47m to progress ADC pipeline

June 7, 2021

Via: Pharma Times

This includes the company’s lead pre-clinical ADC candidate IKS03, a potentially ‘best-in-class’ CD19-targeted asset for B-cell cancers. Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase I clinical trials, and will also be used to […]

Industry, Pharma

Pharma delivers: New campaign celebrates pharma distribution companies’ role during pandemic

June 4, 2021

Via: FiercePharma

Most people don’t normally think about the intricacies of the pharma supply chain, but the COVID-19 pandemic suddenly pushed the topic front and center. Now a new ad campaign from the Healthcare Distribution Alliance celebrates the critical work of healthcare […]

FDA, Industry, Pharma, Regulations

FDA panel backs Provention Bio’s type 1 prevention drug teplizumab

May 28, 2021


The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 10-7 in favour of the benefits of teplizumab outweighing its risks to support approval of the drug to delay type 1 diabetes. The EMDAC based its recommendation on data from […]

Cell and Gene Therapy, FDA, Industry, Pharma, Regulations

FDA accepts filing for Shorla Pharma’s leukaemia treatment

April 23, 2021

Via: EPM Magazine

Shorla Pharma’s SH-111 treatment is being designed as an alternative therapy for T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It will be targeted at paediatric patients over the age of one whose disease has not responded or […]

Industry, News, Pharma

Biotech’s deal refusals led to pricey buyout by Merck

March 5, 2021

Via: Biopharma Dive

Merck, under outgoing CEO Ken Frazier and now retired research chief Roger Perlmutter, has stayed away from large-scale dealmaking. But the pharma has proven an enthusiastic acquirer of early-stage, smaller companies, buying up seven private and public biotechs over the […]

Industry, Pharma

Lyophilization Services for Biopharmaceuticals Market Review Report with Future Aspect Analysis

February 25, 2021

Via: BioSpace

Lyophilization has been popularly employed by the pharmaceuticals industry in parenteral product development. The process has the potential to improve the shelf-life, increase the efficacy of formulations, especially complex injectables, and to make them easier to store and transport. Biopharmaceutical […]

Industry, Pharma

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

December 24, 2020

Via: BioSpace

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that the Company has elected to exercise its acceleration right under the warrant indenture (the “Indenture”) governing the common share […]

Industry, News, Pharma

Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for BPX-01 and BPX-04

September 15, 2020

Via: BioSpace

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent […]

Industry, Pharma

Drug Targets Identified More Discerningly

September 1, 2020

Via: Genetic Engineering and Biotechnology News

Experimental drugs face steep odds. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), out of every 5,000 to 10,000 compounds that enter the discovery and development pipeline, just 5 enter clinical trials, and only 1 receives approval. Other […]